Modulation of Cerebral Blood Flow Using Quercetin, a Nutritional Supplement

Mass General Brigham

Status and phase: Completed; Early Phase 1

Conditions: Problem of Aging; Stroke

Treatments: Dietary Supplement: quercetin/placebo

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT01376011

1K23AG030967-01A1 (U.S. NIH Grant/Contract)

1 K23AG030967-01A1-2

Details and patient eligibility

About

The purpose of this study is to find out if quercetin can increase blood levels of hypoxia-inducible transcription factor 1 (HIF-1 protein) and to see if there is a corresponding increase in blood flow to the brain.

Enrollment: 106 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• healthy volunteers between the ages of 18-75 years old

Exclusion criteria

• subjects taking vasoactive medications
• hypertension or vascular disease
• asthma
• smokers
• pregnant women
• cancer
• diabetes mellitus
• history of seizures
• history of stroke or head trauma
• subjects taking digoxin, cyclosporine,felodipine, estradiol, or quinolone antibiotics
• poor transcranial Doppler insonation windows

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

106 participants in 2 patient groups

healthy young

Experimental group

Treatment:

Dietary Supplement: quercetin/placebo

healthy old

Experimental group

Treatment:

Dietary Supplement: quercetin/placebo